Drugs / PSB202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05003141 | Nov 2021 → Jul 2023 | MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma +1 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSB202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05003141 ↗ |
| Action | Deplete | “to deplete malignant B cells independently of T-cell engagement.” PMID 42216090 ↗ May 2026 |
| Modality | Monoclonal antibody | “PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies” NCT05003141 ↗ |